Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 6/2006

01-06-2006 | Original Article

Early-outgrowth of endothelial progenitor cells can function as antigen-presenting cells

Authors: Masahiro Asakage, Nelson H. Tsuno, Joji Kitayama, Kazushige Kawai, Yurai Okaji, Kentaro Yazawa, Shoichi Kaisaki, Takuya Osada, Toshiaki Watanabe, Koki Takahashi, Hirokazu Nagawa

Published in: Cancer Immunology, Immunotherapy | Issue 6/2006

Login to get access

Abstract

Endothelial progenitor cells (EPCs) have been recently found to exist circulating in peripheral blood of adults, and home to sites of neovascularization in peripheral tissues. They can also be differentiated from peripheral blood mononuclear cells (PBMNCs). In tumor tissues, EPCs are found in highly vascularized lesions. Few reports exist in the literature concerning the characteristics of EPCs, especially related to their surface antigen expressions, except for endothelial markers. Here, we aimed to investigate the surface expression of differentiation markers, and the functional activities of early-outgrowth of EPCs (EO-EPCs), especially focusing on their antigen-presenting ability. EO-EPCs were generated from PBMNCs, by culture in the presence of angiogenic factors. These EO-EPCs had the morphological and functional features of endothelial cells and, additionally, they shared antigen-presenting ability. They induced the proliferation of allogeneic lymphocytes in a mixed-lymphocyte reaction, and could generate cytotoxic lymphocytes, with the ability to lyze tumor cells in an antigen-specific manner. The antigen-presenting ability of EO-EPCs, however, was weaker than that of monocyte-derived dendritic cells, but stronger than peripheral blood monocytes. Since EO-EPCs play an important role in the development of tumor angiogenesis, targeting EPCs would be an effective anti-angiogenic strategy. Alternatively, due to their antigen-presenting ability, EO-EPCs can be used as the effectors of anti-tumor immunotherapy. Since they share endothelial antigens, the activation of a cellular immunity against angiogenic vessels can be expected. In conclusion, EO-EPCs should be an interesting alternative for the development of new therapeutic strategies to combat cancer, either as the effectors or as the targets of cancer immunotherapy.
Literature
1.
Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N (1998) Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 188:1359–1368PubMedCrossRef
2.
Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221–228PubMed
3.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967PubMedCrossRef
4.
Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 18:3964–3972PubMedCrossRef
5.
Asakage M, Kitayama J, Tsuno NH, Komuro Y, Kaisaki S, Hori N, Nagawa H, Takahashi K (2005) Primary malignant melanoma of the esophagus treated by esophagectomy and adjuvant dendritic-cell therapy. J Gastroenterol 40:545–546PubMedCrossRef
6.
Asakage M, Tsuno NH, Kitayama J, Kawai K, Okaji Y, Yazawa K, Kaisaki S, Takahashi K, Nagawa H (2004) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. Anticancer Drugs 15:625–632PubMedCrossRef
7.
8.
Eggermann J, Kliche S, Jarmy G, Hoffmann K, Mayr-Beyrle U, Debatin KM, Waltenberger J, Beltinger C (2003) Endothelial progenitor cell culture and differentiation in vitro: a methodological comparison using human umbilical cord blood. Cardiovasc Res 58:478–486PubMedCrossRef
9.
Fernandez Pujol B, Lucibello FC, Gehling UM, Lindemann K, Weidner N, Zuzarte ML, Adamkiewicz J, Elsasser HP, Muller R, Havemann K (2000) Endothelial-like cells derived from human CD14 positive monocytes. Differentiation 65:287–300PubMedCrossRef
10.
Fernandez Pujol B, Lucibello FC, Zuzarte M, Lutjens P, Muller R, Havemann K (2001) Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur J Cell Biol 80:99–110PubMedCrossRef
11.
12.
Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931–10934PubMed
13.
Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA (1996) Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA 93:13967–13972PubMedCrossRef
14.
Hart PH, Whitty GA, Burgess DR, Croatto M, Hamilton JA (1990) Augmentation of glucocorticoid action on human monocytes by interleukin-4. Lymphokine Res 9:147–153PubMed
15.
Holtl L, Rieser C, Papesh C, Ramoner R, Bartsch G, Thurnher M (1998) CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet 352:1358PubMedCrossRef
16.
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52–58PubMedCrossRef
17.
Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, Park YB (2004) Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 24:288–293PubMedCrossRef
18.
Inaba K, Inaba M, Naito M, Steinman RM (1993) Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med 178:479–488PubMedCrossRef
19.
Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T (2000) Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 97:3422–3427PubMedCrossRef
20.
Levin D, Constant S, Pasqualini T, Flavell R, Bottomly K (1993) Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo. J Immunol 151:6742–6750PubMed
21.
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332PubMedCrossRef
22.
Page C, Rose M, Yacoub M, Pigott R (1992) Antigenic heterogeneity of vascular endothelium. Am J Pathol 141:673–683PubMed
23.
Rehman J, Li J, Orschell CM, March KL (2003) Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107:1164–1169PubMedCrossRef
24.
Risau W, Sariola H, Zerwes HG, Sasse J, Ekblom P, Kemler R, Doetschman T (1988) Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development 102:471–478PubMed
25.
Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP (1998) Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 35:144–151PubMedCrossRef
26.
Seino K, Azuma M, Bashuda H, Fukao K, Yagita H, Okumura K (1995) CD86 (B70/B7-2) on endothelial cells co-stimulates allogeneic CD4+ T cells. Int Immunol 7:1331–1337PubMedCrossRef
27.
Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271–296PubMedCrossRef
28.
Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S (2003) Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 108:2511–2516PubMedCrossRef
29.
Vallee I, Guillaumin JM, Thibault G, Gruel Y, Lebranchu Y, Bardos P, Watier H (1998) Human T lymphocyte proliferative response to resting porcine endothelial cells results from an HLA-restricted, IL-10-sensitive, indirect presentation pathway but also depends on endothelial-specific costimulatory factors. J Immunol 161:1652–1658PubMed
30.
Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S (2001) Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103:2885–2890PubMedCrossRef
31.
Metadata
Title
Early-outgrowth of endothelial progenitor cells can function as antigen-presenting cells
Authors
Masahiro Asakage
Nelson H. Tsuno
Joji Kitayama
Kazushige Kawai
Yurai Okaji
Kentaro Yazawa
Shoichi Kaisaki
Takuya Osada
Toshiaki Watanabe
Koki Takahashi
Hirokazu Nagawa
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/2006
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-005-0057-y

Other articles of this Issue 6/2006

Cancer Immunology, Immunotherapy 6/2006 Go to the issue

Original Article

Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen

Original Article

The enlargement of the hormone immune deprivation concept to the blocking of TGFα-autocrine loop: EGFR signaling inhibition

Short Communication

Expression of CD45 and proliferative response to CD3 as suitable classification markers of patients with gastric adenocarcinoma

Original Article

Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival

Original Article

Flow Cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of Superficial Transitional cell carcinoma of bladder

Perspectives

ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits